Opinion

Video

Treatment Selection and the Use of Combination Therapies in mCRPC

Panelists discuss how radiopharmaceuticals like lutetium-177 prostate-specific membrane antigen (PSMA) may be preferred over systemic therapy in patients with prostate cancer who have high PSMA expression, multiple bone metastases, and limited visceral disease, particularly after progression on standard therapies like androgen receptor pathway inhibitors and taxane-based chemotherapy.

Video content above is prompted by the following:

  • In which scenarios would you be more likely to opt for radiopharmaceuticals for prostate cancer treatment vs systemic therapy?
Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
© 2025 MJH Life Sciences

All rights reserved.